Area of research
Hematology · Genetics
Research interest
Research interests include Medicine, Internal medicine, Mesenchymal stem cell, Oncology, Myeloid leukemia, and Hematology.
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases
Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE
Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
Efficacy and safety of the <scp>C5</scp> inhibitor crovalimab in complement inhibitor‐naive patients with <scp>PNH</scp> (<scp>COMMODORE</scp> 3): A multicenter, <scp>Phase</scp> 3, single‐arm study
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial
Validation of the imatinib-therapy failure model
Imatinib compared with second‐generation tyrosine kinase‐inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial
Identification and Validation of a Prognostic Risk-Scoring Model Based on Ferroptosis-Associated Cluster in Acute Myeloid Leukemia
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
Challenges and advances in clinical applications of mesenchymal stromal cells
C‐Type Lectin‐Like Molecule‐1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study
P-192: Circularly permuted TRAIL (CPT) combined with Thalidomide and Dexamethasone in patients with relapsed/refractory Multiple Myeloma: a randomized, double-blind, placebo-controlled phase 3 study
A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD
A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
Mesenchymal Stromal Cells Treatment Attenuates Dry Eye in Patients With Chronic Graft-versus-host Disease